AERI News and Press, Aerie Pharmaceuticals Inc. From 05/05/22

First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter o...

Aerie Pharmaceuticals (NASDAQ:AERI) Q1 consensus EPS estimate is -$0.65 (+9.7% Y/Y) and consensus revenue estimate is $29.9M (+30.2% Y/Y). AERI is scheduled to announce Q1 earnings results tomorrow, May 5, after market close. Over the last 2 years, AERI has beaten EPS estimates...

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 202...

Abstracts showcase Rhopressa ® / netarsudil, AR-15512 and “ROCK’Ster” Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, to...

Data adds to real-world use and clinical research on netarsudil (Rhopressa ® ) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced th...

Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) traded at a new 52-week high today of $74.60. This new high was reached on above average trading volume as 51.6 million shares traded hands, while the average 30-day volume is approximately 931,000 shares. In the past 52 weeks, shares of...

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary...

Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) traded today at $74.60, eclipsing its 52-week high. So far today approximately 51.5 million shares have been exchanged, as compared to an average 30-day volume of 972,000 shares. Aerie Pharmaceuticals Inc. share prices have moved between...

Gainers: Array Technologies (ARRY) +13.5%. UTA Acquisition (UTAA) +12.8%. Gogo (GOGO) +10.5%. CarParts.com (PRTS) +5.9%. Sana Biotechnology (SANA) +5.8%. Losers: Anghami (ANGH) -9.0%. GeoGlobal Resources (GGR) -5.1%. Spero Therapeutics (SPRO) -4.9%. Aerie Pharmaceuticals (AERI) -4.9...

Aerie Pharmaceuticals (NASDAQ:AERI) has appointed Peter F. Lang as Chief Financial Officer, effective March 18, 2022. “I am pleased to welcome Peter to our leadership team,” said Raj Kannan, Chief Executive Officer. “His extensive experience in investment bankin...